ORIC: Late-stage cancer programs advance with strong funding, key data, and safety differentiation ahead
Two late-stage oncology programs are advancing, with rinzimetastat in phase III for prostate cancer and enozertinib targeting lung cancer. Key differentiators include safety and potential resistance advantages, with major data readouts and program updates expected over the next 12—18 months.Based o…